What To Know About Artelo Bio And Trinity College's Partnership For Cannabinoid And Cancer Research

Earlier this month, Artelo Biosciences Inc (NASDAQ: ARTL) announced a partnership with Trinity College in Dublin to research a new drug with potential in anorexia associated with cancer. 

Led by Richard Porter, associate professor at Trinity’s School of Biochemistry and Immunology, the researchers will work with Artelo’s peripherally selective cannabinoid receptor agonist, ART27.13, in preclinical models of human cancer cachexia.

Cachexia is a wasting syndrome that affects up to 80% of all cancer patients and is believed to hasten death.

Artelo is a clinical-stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signalling pathways — including the endocannabinoid system.

Cannabinoids And …

Full story available on Benzinga.com

More What To Know About Artelo Bio And Trinity College's Partnership For Cannabinoid And Cancer Research